News|Articles|July 7, 2026

Five Gastrointestinal Cancer Abstracts You May Have Missed at ESMO GI 2026

Fact checked by: Tim Cortese, Roman Fabbricatore, Justin Mancini

Catch up on key data in colorectal, pancreatic, and hepatocellular cancers presented at the ESMO Gastrointestinal Cancers Congress 2026.

The European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress 2026 delivered a mix of practice-informing and practice-questioning data across the gastrointestinal (GI) cancer landscape, from a phase 3 trial evaluating a KRAS G12C inhibitor combination that failed to beat chemotherapy in colorectal cancer to early phase 1/2 signals for a new RAS(ON) inhibitor in pancreatic cancer. Investigators also reported mixed results for chemoembolization-based combinations in hepatocellular carcinoma (HCC) and landmark long-term survival data for a checkpoint inhibitor doublet in refractory microsatellite-stable (MSS) colorectal cancer (CRC).

Related to this article

In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.

October 9th, 2026

Selcodebart Yields Hematologic Responses in Anemia From Myelofibrosis

In the phase 2 RALLY-MF study, selcodebart produced a 55% major response rate among evaluable non–transfusion-dependent patients with myelofibrosis.

October 2nd, 2026

Fractionated SRS Improves Surgical Bed Control After Brain Metastasis Resection

In the phase 3 Alliance A071801 trial, postoperative fractionated SRS improved surgical bed control vs single-fraction SRS without added toxicity.

October 2nd, 2026

Preoperative SBRT Shows High Resection Rates in Pancreatic Adenocarcinoma

William A. Hall, MD, reviews resection rates, surgical complications, and SBRT target volumes from the SOFT Preop study in pancreatic cancer.

Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.

October 2nd, 2026

Understanding the KRAS Mutation Landscape in Biliary Tract Cancer

Andy Liao, MD, discusses the distribution of KRAS mutations in biliary tract cancer and the different classes of KRAS inhibitors in development.

October 1st, 2026

What Drove the SBRT Quality-of-Life Advantage in Pancreatic Cancer?

William A. Hall, MD, explains how fewer visits, no concurrent chemotherapy, and adaptive MRI guidance may have preserved quality of life with SBRT.

October 1st, 2026

SBRT Preserves Quality of Life Before Pancreatic Cancer Surgery

William A. Hall, MD, discussed how preoperative SBRT may serve as a platform for novel systemic therapies in pancreatic adenocarcinoma.

October 1st, 2026

SBRT Matches Disease Control of Prostatectomy in Localized Prostate Cancer

At 8 years, SBRT and radical prostatectomy had similar disease control in the PACE-A trial, with less urinary incontinence after SBRT.

Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.

October 1st, 2026

Early Clinical Data Show KRAS Inhibitors Can Work in Cholangiocarcinoma

Chih-Yi “Andy” Liao, MD, discusses early clinical data for KRAS G12C and G12D inhibitors in cholangiocarcinoma, noting that trials are just getting started.